Navigation Links
Insmed to Host Fourth Quarter and 2011 Year-End Earnings Conference Call
Date:2/28/2012

MONMOUTH JUNCTION, N.J., Feb. 28, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, will host a conference call on Tuesday, March 13th, 2012, at 8:30 AM ET, to discuss its financial results for the fourth quarter and year-end 2011.  Insmed intends to issue its quarterly and year-end financial results press release before the market opens on March 13th.

To participate in the live conference call, please dial 800-798-2864 (U.S. callers) or 617-614-6206 (international), and provide passcode 48373405.  A live webcast of the call will also be available at http://www.media-server.com/m/p/xfhdp2ne.  Please allow extra time prior to the webcast to register, download and install any necessary audio software.

The webcast will be archived for 30 days, and a telephone replay of the call will be available for seven days, beginning at 10:30 AM ET on March 13th, at 1-888-286-8010 (U.S. callers) or 1-617 801-6888 (international), using passcode 11615475.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on the development of innovative inhaled pharmaceuticals for the site-specific treatment of serious lung diseases.  Insmed's primary focus is on the development of inhaled antibiotic therapy delivered via proprietary advanced liposomal pulmonary technology in areas of high unmet need.  For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to our financial position, results of operations, the status and the results of preclinical studies and clinical trials and preclinic
'/>"/>

SOURCE Insmed Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy
2. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
3. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
4. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
5. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
6. Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
7. Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
8. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
9. Insmed to Host Third Quarter 2010 Conference Call
10. Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2010
11. NASDAQ Grants Insmed Incorporated 180-Day Extension to Regain Compliance with Minimum Bid Price Rule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... HOUSTON , TX and VANCOUVER , May ... "Company") (TSX-V: EPI) announced today that it has received notification ... in the US that the Company,s IND application, filed March ... by the FDA of additional chemistry and pharmaceutical data related ... and a Certificate of Analysis on drug product. ...
(Date:5/4/2015)... NEW HAVEN, Conn. , May 4, 2015 ... been chosen by the American Optometric Association (AOA) ... care delivery and outcomes for the millions of ... Measures and Outcomes Registry for Eyecare ... and will securely facilitate efficient secondary uses of ...
(Date:5/1/2015)... 2015   Intarcia Therapeutics, Inc. today announced ... Vice President, Human Resources, reporting directly to Kurt ... new key member of the senior leadership team, Mr. ... Team to assure the Company advances its business, brings ... core values and its dynamic culture. Another essential goal ...
Breaking Medicine Technology:ESSA Pharma Inc. Receives FDA Response on IND Application 2ESSA Pharma Inc. Receives FDA Response on IND Application 3ESSA Pharma Inc. Receives FDA Response on IND Application 4American Optometric Association, Prometheus Research to Create Transformative Health Outcomes Registry 2Intarcia Appoints James P. Brady Vice President, Human Resources 2Intarcia Appoints James P. Brady Vice President, Human Resources 3Intarcia Appoints James P. Brady Vice President, Human Resources 4
... 1, 2010 Flextronics (Nasdaq: FLEX ... a dedicated, 180,000 square foot facility in Senai, ... rise in demand from medical OEMs, while providing ... needs.  Flextronics Medical,s new clean room manufacturing, ISO13485 ...
... ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
Cached Medicine Technology:Flextronics Medical to Open Malaysia Facility to Complement Existing Low-Cost Footprint and Support Growth for Manufacturing Services 2Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C 2Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C 3Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C 4Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C 5Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C 6Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C 7Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C 8Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C 9Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C 10Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C 11Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C 12Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C 13Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C 14
(Date:5/4/2015)... Sylvia Hawthorn-Deppen shared her experiences living ... remind others in similar situations that they were not alone, ... and Discovery of New Energy” (published by Balboa Press). This ... a renewed press campaign. , “I have spent nearly 60 ... Hawthorn-Deppen says. “As an adolescent I got into trouble with ...
(Date:5/4/2015)... 04, 2015 Fast on the heels ... Trace Amounts, and Allison Folmar, JD, join over 150 ... internationally. , On Sunday, May 24, the conference presents ... possible?" Are you interested in Ryan Hinds' recovery story? ... our war against autism was written by Marcia ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Sara Soulati, ... physician practice management firm in Los Angeles associated with ... the patent-pending status of The Sara Soulati Health For ... in 2010, is a lifestyle modification and disease prevention ... 2015 to the U. S. Patents and Trademarks Office ...
(Date:5/3/2015)... CA (PRWEB) May 03, 2015 Leading ... (CFHI), announced it will be awarding the 2015 Harris ... Knight and Selemawit Ghebrendrias, are the deserving recipients of ... for global service, Harris Llewellyn Wofford. The two recipients ... and passion for global health. , CFHI is ...
(Date:5/3/2015)... San Mateo, CA (PRWEB) May 03, 2015 ... newest service, MnemeTherapy® at two upcoming area seminars. The ... during the PSA Annual Regional Stroke Conference to be ... will be offered on Wednesday, May 13 during the ... Crowne Plaza. , “These seminars offer an excellent ...
Breaking Medicine News(10 mins):Health News:Author launches new press campaign for 2012 book ‘Wheel’ 2Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 2Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 3Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 4Health News:CEO Sara Soulati Announces Patent-Pending Designation For The Sara Soulati Health For Life Program 2Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 2Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 3Health News:NuevaCare Introduces MnemeTherapy® Approach to Care for Elderly Patients with Alzheimer’s, Stroke and Other Types of Neurodegenerative Conditions 2
... damage if used improperly , TUESDAY, June 30 (HealthDay ... that the maximum dose for Tylenol and other pain ... , The advisers recommended lowering the maximum dose of ... and other medications. , Part of the problem, according ...
... pandemic since April study , , FLEMINGTON, N.J., June ... that more than one-third of physicians (37%) reported that there ... could result in a catastrophic pandemic, the highest level since ... there was "somewhat of a risk" for a pandemic. , ...
... Foods , LLC announced today that it is voluntarily recalling ... its stores between May 9th and May 15th. This ... by the JBS Swift Beef Company, which yesterday voluntarily expanded ... be contaminated with E. coli 0157:H7 to approximately 380,000 pounds ...
... can lead to serious injury , , , ... thrill of skateboarding. They learn to master their skills of ... American College of Foot and Ankle Surgeons (ACFAS), such tricks, ... and ankle injuries. , , Foot and ankle ...
... [Brown University] A front portion of the brain that ... according to new Brown University research. This section of ... different pronunciations of the same speech sound (such as a ... have solved a mystery. "No two pronunciations of the ...
... , NEW YORK, June 30 A new report on ... singles out Hospital for Special Surgery as the only hospital ... surgical site infection (SSI) compared to the state average for ... as a best practice," said Thomas P. Sculco, M.D., surgeon-in-chief ...
Cached Medicine News:Health News:FDA Advisers Recommend Smaller Doses of Acetaminophen 2Health News:More than One-Third of Docs Say Risk Level Rising for Potential H1N1 Flu Pandemic 2Health News:More than One-Third of Docs Say Risk Level Rising for Potential H1N1 Flu Pandemic 3Health News:WinCo Foods Voluntarily Recalls Beef and Ground Beef Sold at Some Stores Between May 9 and May 15, 2009 Due to Possible Contamination 2Health News:Surgeons Warn: Skateboarding Tough on Feet, Ankles 2Health News:Brain section multitasks, handling phonetics and decision-making 2Health News:Hospital for Special Surgery is Only New York Hospital with Significantly Lower Surgical Site Infection Rate for Hip Replacement Compared to State Average 2
... The next generation Powerheart AED has ... our flagship, feature-rich AED offering. The ... new customer-friendly features such as more ... new lighter weight, redesigned form factor, ...
... Plus™ is the best EMR value for ... in mind, Charting Plus™ relies heavily on ... features to improve documentation quality and increase ... content is specific to your medical specialty. ...
... the vast information needs of orthopedics specialty. ... for common orthopedics complaints, history of present ... also includes orthopedics specific ICD and CPT ... charges and quickly generate electronic Superbill at ...
... Maximo, Model 7303, incorporates new advances in CRT ... Proven Marquis ICD Platform. With this device, ... in 9 seconds or less throughout the life ... (14% increase in longevity over InSync II Marquis) ...
Medicine Products: